Halozyme Therapeutics, Inc. HALO
103.63 USD -19.33 (-15.72%)
At closeNov 6, 2026, 7:45 PM EST
103.75 +0.12 +0.12%
After hours · Nov 6, 7:45 PM ET
102.53 Day range 118.26
61.63 52-week range 131.18
- YTD
- +53.98%
- 1 year
- +51.53%
Analyst view
Consensus: buy
Buy
Price target (mean) 108.89 +5.1% upside
Now 103.63
- Target (low)
- 79.00
- Target (mean)
- 108.89
- Target (high)
- 130.00
Ratings (0m) 9 7 buy · 2 hold · 0 sell
- Strong buy2
- Buy5
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 9
- 2 months ago 9
- 3 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.62 | 2.46 – 2.75 | -0.24 | +1193.3% | 537.59M | +19.0% | 6 |
| Next quarter | 2.33 | 2.32 – 2.35 | 1.60 | +45.8% | 484.37M | +28.6% | 3 |
| Current year | 8.84 | 8.65 – 8.98 | 4.15 | +113.1% | 1.88B | +34.7% | 6 |
| Next year | 10.69 | 10.11 – 11.35 | 8.84 | +20.9% | 2.10B | +11.7% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Nov 6, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Nov 6, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Nov 3, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Oct 13, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 8, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Oct 8, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 2, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2026 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Aug 7, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 7, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Aug 7, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 7, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 21, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 12, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Apr 29, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 19, 2026 | Benchmark | Maintained | Buy | Buy |
| Feb 19, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Jan 8, 2026 | TD Cowen | Maintained | Buy | Buy |
| Dec 19, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 28, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 18, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Nov 4, 2025 | Citizens | Maintained | Market Outperform | Market Outperform |
| Oct 27, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Oct 20, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 15, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 14, 2025 | Leerink Partners | Upgrade | Underperform | Market Perform |
| Oct 2, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 24, 2025 | Benchmark | Maintained | Buy | Buy |
| Sep 22, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |